A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia

The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.

本研究旨在比较两种抗精神病药物（antipsychotic medications）——利培酮长效注射剂（Risperdal® Consta®）与阿立哌唑（Abilify®）——在为期2年的治疗周期内，用于精神分裂症（schizophrenia）患者的长期维持治疗的有效性。